X

Trial Profile

Phase I trial investigating DCR-PH1 in healthy volunteers

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DCR PH1 (Primary)
Indications Primary hyperoxaluria; Primary hyperoxaluria type 1
Focus Adverse reactions; First in man; Proof of concept
Sponsors Dicerna Pharmaceuticals

Most Recent Events

10 Aug 2017 Status changed from recruiting to discontinued according to a Dicerna Pharmaceuticals media release.
26 Sep 2016 According to a Dicerna Pharmaceuticals media release, data from this study were presented at the 17th Congress of the International Pediatric Nephrology Association.
21 Dec 2015 According to a Dicerna Pharmaceuticals media release, results from this trial are expected to be available in the second half of 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com